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Introduction: Stereotactic body radiotherapy (SBRT) has been 
increasingly utilized for medically inoperable early stage non–small-
cell lung cancer. However, a lower biological equivalent dose (BED) 
is often used for central tumors given toxicity concerns, potentially 
leading to decreased local control (LC). We compared survival, 
LC, and toxicity outcomes for SBRT patients with centrally versus 
peripherally located tumors.
Methods: We included patients with primary cT1-2N0M0 non–
small-cell lung cancer treated with SBRT at our institution from 
September 2007 to August 2013 with follow-up through August 
2014. Central tumor location was defined as within 2 cm of the proxi-
mal bronchial tree, heart, great vessels, trachea, or other mediastinal 
structures. Kaplan–Meier analysis and multivariable Cox regression 
modeling were used for overall survival (OS) and LC, and the χ2 test 
and multivariable logistic regression modeling were used for toxicity.
Results: We included 251 patients (111 central, 140 peripheral) with 
median follow-up of 31.2 months. Patients with central tumors were 
more likely to be older (mean 75.8 versus 73.5 years; p = 0.04), have 
larger tumors (mean 2.5 cm versus 1.9 cm; p < 0.001), and be treated 
with a lower BED (mean 120.2 Gy versus 143.5 Gy; p < 0.001). 
Multivariable analysis revealed that tumor location was not associ-
ated with worse OS, LC, or toxicity. Patients with central tumors 
were less likely to have acute grade greater than or equal to three tox-
icity than those with peripheral tumors (odds ratio: 0.24; p = 0.02).
Conclusions: Central tumor location did not predict for inferior 
OS, LC, or toxicity following SBRT when a lower mean BED was 
utilized.
Key Words: Stereotactic body radiation therapy, Central, Non–
small-cell lung cancer, toxicity.
(J Thorac Oncol. 2015;10: 832–837)
Stereotactic body radiotherapy (SBRT) has been increas-ingly utilized in the management of medically inoper-
able early stage non–small-cell lung cancer (NSCLC). For 
peripheral tumors, the Radiation Therapy Oncology Group 
(RTOG) 0236 phase II trial demonstrated a 3-year primary 
tumor control of 97.6% and 3-year lobar control of 90.6% 
when a dose of 54 Gy was delivered in three fractions.1 
However, there is considerable concern that treatment of 
centrally located tumors could lead to increased toxicity. 
A phase II trial at the University of Indiana noted increased 
grade 3–5 toxicity for patients with central tumors (within 
2 cm of the proximal bronchial tree) compared with periph-
eral tumors (27.3% versus 10.4%; p = 0.09) using SBRT 
prescribed to at least 54 Gy in three fractions (corrected 
for tissue heterogeneity).2,3 This led to the exclusion of 
patients with central tumors from RTOG 0236, as well as 
the formulation of a separate dose escalation study for cen-
tral tumors using a lower biological equivalent dose (BED; 
RTOG 0813).
Experience in treating central tumors with SBRT sug-
gests that regimens using more than three fractions may be 
reasonably well tolerated.4–7 However, decreasing the BED 
with a more conservative dose-fractionation regimen could 
be concerning for decreased local control (LC) and possi-
bly overall survival (OS). Two large multiinstitutional stud-
ies have suggested that a BED of at least 100–105 Gy may 
be necessary to achieve optimal LC outcomes,8,9 although 
another multiinstitutional tumor control probability model 
has suggested greater LC with a BED of 151.2 Gy (54 Gy 
in three fractions) compared with 100 Gy (50 Gy in five 
fractions).10
The aim of this study was to examine a large, single-
institution experience with SBRT for both peripherally and 
centrally located NSCLC. Our goal was to assess whether or 
not central tumor location would predict for worse OS, LC, 
or acute and late toxicity in an era of more conservative dose-
fractionation regimens for centrally located tumors.
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PATIENTS AND METHODS
Patient Selection
We prospectively maintained an institutional data-
base of patients treated with SBRT for primary NSCLC 
from September 2007 to August 2013. From this database, 
we selected all patients with AJCC 7th edition stage cT1-
2N0M0 disease, who had at least one follow-up appointment 
with medical oncology, radiation oncology, or pulmonology. 
Central tumor location was defined as within 2 cm of the prox-
imal bronchial tree (RTOG definition2) or within 2 cm of the 
heart, trachea, pericardium, or vertebral body, but 1 cm away 
from the spinal canal (based on a modification of the MD 
Anderson Cancer Center definition4).
Treatment
Patients were immobilized in a customized full-
length vacuum cushion and underwent a four-dimensional 
computed tomography (CT) scan during free breathing. 
Abdominal compression was used only for select cases in 
which tumor excursion exceeded 1 cm. An internal target 
volume was contoured to include the entire respiratory 
excursion of the tumor using the Advantage Workstation 
(GE Healthcare, Waukesha, WI). An isovolumetric 7 mm 
expansion was added to the internal target volume create a 
planning tumor volume (PTV). The heart, lung, esophagus, 
proximal tracheobronchial tree, spinal cord, and brachial 
plexus were contoured.
Treatment plans were generated using Eclipse (Varian 
Medical Systems, Palo Alto, CA), with tissue heterogeneity 
corrections based on the anisotropic analytical algorithm. 
Priority was given to PTV coverage, at the expense of normal 
tissue exposure. All plans were normalized such that 95% 
of the PTV was covered by 100% of the prescription dose 
and 99% of the PTV was covered by at least 90% of the pre-
scription dose, with an expected maximum heterogeneity of 
111–143% within the tumor (corresponding to 70–90% of 
the maximum dose at the edge of the PTV). A higher prior-
ity was given to obtaining full coverage of the PTV to the 
prescription dose than to remaining within RTOG guidelines 
for organs at risk. Patients were treated initially with mul-
tiple nonopposed, noncoplanar beams, or more recently with 
a dynamic conformal arc technique (described in detail by 
Ross et al.11). Intensity-modulated radiation therapy using 
static fields or volumetric modulated arc therapy was reserved 
for the minority of cases when forward planning resulted in 
an inferior plan.
All patients were treated in three to five fractions on 
nonconsecutive days, completing therapy within 15 calen-
dar days. Cone-beam CT image guidance was used for all 
patients.
Follow-Up
Follow-up included a history and physical examina-
tion approximately 4 weeks after completing SBRT. Patients 
were then evaluated clinically and with a noncontrast chest 
CT every 3 to 4 months for the first year, then every 3–6 
months thereafter. Local failure was defined as a recurrence 
within the treated lobe as determined by biopsy or clinical 
judgment of the treating physician. OS was recorded based 
on most recent evidence of vital status in the medical record 
or by death date, based on obituary or in-hospital death. LC 
and toxicities were followed as of last radiographic or clinical 
follow-up.
Treatment-related toxicity was scored with the National 
Institute of Health Common Terminology Criteria for Adverse 
Events (CTCAE), version 4.0. An acute toxicity was defined 
as a treatment-related side effect occurring within 90 days of 
the first fraction; a late toxicity was one that occurred after 
this time.
Data Analysis
The BED was calculated using the linear quadratic 
equation, assuming α/β = 10. For univariable analysis, the χ2 
test was used for categorical variables, and the student’s t test 
was used for continuous variables. The Kaplan–Meier method 
was used to estimate OS and LC. Subgroups were compared 
with the log-rank test. Additional univariable and multivari-
able analyses for time-to-event analyses were performed 
using Cox proportional hazards modeling. Acute toxicity 
and late toxicity were evaluated with the χ2 test and multi-
variable logistic regression modeling. Multivariable analyses 
adjusted for potential covariates, including patient factors like 
age, sex, and performance status; clinical factors like biopsy 
versus nonbiopsy diagnostic method, tumor histology, tumor 
size, and T-stage; and treatment-related factors like BED, 
total number of targets, maximum lung point dose, mean lung 
dose, volume of lung receiving greater than or equal to 5 Gy 
(V5), volume of lung receiving greater than or equal to 10 Gy 
(V10), and volume of lung receiving greater than or equal to 
20 Gy (V20). All analyses were performed with SPSS version 
19 (IBM, Armonk, NY).
This study was granted approval from the institutional 
review board at our institution.
RESULTS
There were 251 patients with 272 tumors included in 
this analysis, among whom 111 patients (44.2%) received 
SBRT for centrally located tumors. Median follow-up was 
31.2 months for OS and 21.4 months for all other outcomes. 
A total of 181 patients (72.1%) had biopsy-proven NSCLC, 
and 82 patients (32.7%) had invasive mediastinal staging. 
Patients with central tumors were more likely to be older 
(mean 75.8 versus 73.5 years; p = 0.04), have larger tumors 
(mean 2.5 cm versus 1.9 cm; p < 0.001), undergo invasive 
mediastinal staging (46.8% versus 21.4%; p < 0.001), and 
be treated with a lower BED (mean 120.2 Gy versus 143.5 
Gy; p < 0.001) compared with those with peripheral tumors. 
The BED used for peripheral tumors was 151.2 Gy (54 Gy in 
three fractions) in 80.0% of patients, whereas BED for cen-
tral tumors was more variable (151.2 Gy in 36.9% of patients, 
112.5 Gy [50 Gy in four fractions] in 30.6% of patients, and 
100 Gy [50 Gy in five fractions]) in 17.1% of patients. There 
were no other significant differences in patient, clinicopatho-
logic, or treatment-related factors between patients with cen-
tral versus peripheral tumors (Table 1).
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Overall, most acute and late grade 2 and grade greater 
than or equal to three toxicities manifested as dyspnea or 
pneumonitis for both central and peripheral tumors, in addi-
tion to relatively frequent grade 2 chest wall pain (Table 2). 
Although there were no significant differences in acute grade 
greater than or equal to two, late grade greater than or equal 
to two, and late grade greater than or equal to three toxicity 
by tumor location on univariable and multivariable analysis, 
acute grade greater than or equal to three toxicity was sig-
nificantly less frequent in patients with central tumors com-
pared with peripheral tumors (4.5% versus 12.9%; p = 0.03; 
adjusted OR: 0.24, 95% confidence interval [CI]: 0.07–0.82; 
p = 0.02; Table 3).
Kaplan–Meier analysis revealed that tumor location 
was not associated with OS (71.6% central versus 71.0% 
peripheral at 2 years, median 34.8 months central [95% CI: 
27.1–42.5 months] versus 36.1 months peripheral [95% 
CI: 29.1–43.0]; p = 0.30; Fig. 1), LC (87.1% central versus 
88.6% peripheral at 2 years; p = 1.00; Fig. 2), regional nodal 
control (88.6% central versus 90.4% peripheral at 2 years; 
p = 0.95; Supplementary Figure 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A797), or distant con-
trol (91.7% central versus 88.6% peripheral at 2 years; 
Supplementary Figure 2, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A798). Among the 21 local recur-
rences within the treated lobe for which we could verify 
the location of the recurrence relative to the target volume, 
12 occurred within the PTV. After controlling for potential 
covariates like age and tumor size, Cox proportional hazards 
modeling also showed no significant association between 
tumor location and OS (adjusted hazard ratio: 0.84, 95% CI: 
0.55–1.28; p = 0.41) or LC (adjusted hazard ratio: 1.09, 95% 
CI: 0.45–2.66; p = 0.85; Table 3).
DISCUSSION
To the best of our knowledge, this study represents the 
largest and most comprehensive analysis in North America 
comparing OS, LC, and toxicity outcomes of central versus 
peripheral NSCLC treated with SBRT. Our practice has been 
to treat central tumors with a more conservative dose-frac-
tionation scheme than that used for peripheral tumors, which 
is reflected in the lower mean BED of patients with central 
tumors. After this strategy, we found that our patients with 
central tumors had noninferior OS, LC, and toxicity com-
pared with those with peripheral tumors.
Our early experience treating centrally located lung tumors 
(both primary NSCLC and metastatic lesions) was reported by 
Rowe et al.7. A total of 47 patients with 51 central lesions were 
evaluated, with a median follow-up of 11.3 months (range: 
4.8–40.8 months). Toxicity grade greater than or equal to three 
occurred in five patients (10.6%) and local recurrences occurred 
in two patients (4.3%). Both patients who had local recurrences 
were treated with a median BED of 76 Gy, compared with 112.5 
Gy for the patients without local recurrence (p = 0.04). The 
2-year lobar LC was 100% for those receiving BED greater than 
or equal to 100 Gy compared with 80% for those receiving BED 
less than 100 Gy (p = 0.02). Based at least in part on this initial 
experience, the majority of patients in the more recent era were 
treated with a higher BED. In this updated analysis, there was no 
difference in LC by BED level, likely reflecting the fact that few 
patients in either cohort were treated with BED less than 100 Gy.
TABLE 1.  Patient, Clinicopathologic, and Treatment-Related Characteristics for Patients Treated for Central versus Peripheral 
Tumors (n = 251)
Characteristic Central (n = 111) Peripheral (n = 140) p Value
Patient
  Age (mean ± SE, yr) 75.8 ± 0.8 73.5 ± 0.8 0.04
  Sex (women vs. men) 47 (42.3%) 65 (46.4%) 0.53
  ECOG PS (0–1 vs. ≥2) 84 (75.7%) 104 (74.3%) 0.88
Clinicopathologic
  Diagnostic method (biopsy vs. no biopsy) 83 (74.8%) 98 (70.0%) 0.48
  Invasive mediastinal staging (yes vs. no) 52 (46.8%) 30 (21.4%) <0.001
  Histology (adenocarcinoma vs. other) 31 (27.9%) 50 (35.7%) 0.22
  Tumor size (mean ± SE, cm) 2.5 ± 0.1 1.9 ± 0.1 <0.001
  T-stage (T2 vs. T1) 31 (27.9%) 20 (14.3%) 0.01
Treatment-related
  BED (mean ± SE, Gy) 120.2 ± 2.5 143.5 ± 1.5 <0.001
  Number of targets (1 vs. ≥2) 105 (91.3%) 132 (89.8%) 0.83
  Maximum lung point dose (mean ± SE, Gy) 70.3 ± 4.6 61.2 ± 0.7 0.08
  Mean lung dose (mean, Gy) 4.2 ± 0.2 4.8 ± 0.5 0.26
  Lung V5 (mean, %) 24.2 ± 3.2 22.2 ± 1.1 0.59
  Lung V10 (mean, %) 12.4 ± 0.6 12.1 ± 0.6 0.74
  Lung V20 (mean, %) 5.4 ± 0.3 5.3 ± 0.3 0.76
ECOG PS, Eastern Cooperative Oncology Group performance status; V5, volume of lung receiving ≥5 Gy; V10, volume of lung receiving ≥10 Gy; V20, volume of lung receiving 
≥20 Gy.
BDE, biological equivalent dose.
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One likely explanation for our encouraging results 
for patients with central tumors is related to the increased 
utilization of more conservative dose-fractionation regi-
mens for these patients. Among our cohort of patients with 
centrally located tumors, the majority received 50 Gy in 
four or five fractions (BED 112.5 or 100 Gy, respectively). 
Importantly, those with central lesions experienced lower 
and similar rates of acute and late grade greater than or 
equal to three toxicity rates, respectively, compared with 
those with peripheral disease. These results contrast with 
the high grade greater than or equal to three toxicity rates 
observed in the early experience of the University of 
Indiana phase II trial treating central tumors to at least 54 
Gy in three fractions.1 Furthermore, our findings are con-
sistent with those of a recent systematic review of 20 pub-
lications including outcomes for 563 central lung tumors, 
the majority of which were treated with SBRT in four to 
eight fractions. Central versus peripheral tumor location 
did not impact OS, with LC greater than or equal to 85% 
(when BED greater than or equal to 100 Gy) and grade 
greater than or equal to three toxicities less than 9% found 
for patients with central tumors overall.12
Even with the delivery of a relatively low BED in five 
fractions, caution must still be utilized when treating central 
tumors. A tumor control probability model from the Elekta 
Collaborative Lung Research Group has suggested greater 
LC with a BED of 151.2 Gy (54 Gy in three fractions) com-
pared with 100 Gy (50 Gy in five fractions).10 There have also 
been reports of grade 5 toxicities, including fatal hemoptysis 
from central airway necrosis 8 months after receiving SBRT 
to 50 Gy in five fractions.13 A similar grade 5 toxicity after 
SBRT to 50 Gy in five fractions was described in detail by 
Rowe et al.7
Despite the risk of decreased LC and increased tox-
icities for central tumors compared with peripheral tumors, 
there continues to be considerable interest in treating cen-
trally located NSCLC with SBRT. In an analysis of 117 sur-
vey responses from practicing radiation oncologists, Daly et 
al.14 found that 58% of practitioners would recommend SBRT 
in the absence of a clinical protocol and 23% would offer 
SBRT on a clinical protocol for a patient with a cT1aN0M0 
central tumor with a negative mediastinal workup. Among 
those who would recommend SBRT, 65% would recommend 
50–55 Gy in five fractions, 18% would recommend 48–50 Gy 
in four fractions, 7% would recommend 54–60 Gy in three 
fractions, and 9% would recommend 60 Gy in 8–10 fractions.
In addition, alternative hypofractionation schemes 
involving 10 or more fractions continue to be explored for 
centrally located lung tumors. Chang et al.15 attempted 50 
Gy in four fractions for 100 patients who fulfilled the crite-
ria for central tumor location, but if normal tissue constraints 
were exceeded and optimal coverage could not be reached, 70 
Gy in 10 fractions (BED 119.0 Gy) was utilized in 18% of 
patients. LC outcomes for the subgroup receiving 70 Gy in 10 
fractions were not reported; however, Soliman et al.16 utilized 
48–60 Gy in 12–15 fractions (BED 67.2–84.0 Gy), achieving 
an actuarial 2-year LC rate of 76.2%. However, only 13 of 
124 tumors (10.5%) were centrally located. Further study will 
TABLE 2.  Toxicity Grade and Type of Grade 2 and Grade 
3–5 Toxicity for Patients Treated for Central versus Peripheral 
Tumors (n = 251)
Central (n = 111) Peripheral (n = 140)
Acute toxicity grade
  0 51 (45.9%) 74 (52.9%)
  1 31 (27.9%) 21 (15.0%)
  2 24 (21.6%) 27 (19.3%)
  3 4 (3.6%) 17 (12.1%)
  4 1 (0.9%) 1 (0.7%)
  5 0 (0.0%) 0 (0.0%)
Late toxicity grade
  0 75 (67.6%) 80 (57.1%)
  1 15 (13.5%) 20 (14.3%)
  2 12 (10.8%) 27 (19.3%)
  3 7 (6.3%) 12 (8.6%)
  4 1 (0.9%) 1 (0.7%)
  5 1 (0.9%) 0 (0.0%)
Acute grade 2 toxicity type
  Dyspnea/pneumonitis 12 14
  Fatigue 4 7
  Chest wall pain 2 1
  Esophagitis 4 2
  Hemoptysis 0 0
  Dermatitis 0 3
  Brachial plexopathy 0 0
Late grade 2 toxicity type
  Dyspnea/pneumonitis 9 13
  Fatigue 0 0
  Chest wall pain 1 14
  Esophagitis 1 0
  Hemoptysis 0 0
  Dermatitis 0 0
  Brachial plexopathy 1 0
Acute grade 3–5 toxicity type
  Dyspnea/pneumonitis 3* 14*
  Fatigue 1 2
  Chest wall pain 0 0
  Esophagitis 1 0
  Hemoptysis 0 1
  Dermatitis 0 0
  Brachial plexopathy 0 0
Late grade 3–5 toxicity type
  Dyspnea/pneumonitis 7* 11*
  Fatigue 0 0
  Chest wall pain 0 2
  Esophagitis 0 0
  Hemoptysis 2** 0
  Dermatitis 0 0
  Brachial plexopathy 0 0
*, 1 grade 4; **, 1 grade 5.
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be needed to assess the effectiveness of similar dose-fraction-
ation regimens for larger populations of patients with central 
lung tumors.
Limitations of this study include those inherent to 
retrospective analyses, even those performed with pro-
spectively collected data. A certain degree of selection 
bias cannot be excluded, especially because patients with 
peripherally located tumors were less likely to undergo 
invasive mediastinal staging and may have been more 
likely to harbor occult node-positive disease. Second, it 
is challenging to separate fully the effect of tumor loca-
tion from BED in this study, given the heterogeneity of 
dose-fractionation regimens delivered, especially among 
patients with centrally located tumors. We attempted to 
account for this limitation by utilizing multivariable mod-
eling adjusting for BED, as well as sensitivity analyses 
with BED stratification. Third, our a priori definition of 
central tumor location is broader than that used by RTOG 
0236, to include tumors at high risk of toxicity due to their 
close proximity to critical structures outside the region 
immediately surrounding the proximal bronchial tree. This 
definition allows for the inclusion of patients with signifi-
cant dose to mediastinal structures, so that the analysis of 
dose is more valid and complete. We recognize that this 
definition of central tumor location may include tumors 
that some radiation oncologists might consider peripheral. 
Finally, longer follow-up will be needed to assess for late 
toxicities and local recurrences.
In conclusion, we found that patients with centrally 
located NSCLC who received SBRT appeared to have non-
inferior toxicity, likely due to more conservative dose-frac-
tionation schemes. Despite older age, larger tumor size, and 
lower BED, patients with central tumors had similar OS and 
LC as those with peripheral tumors. Although we await the 
results of RTOG 0813, an ongoing phase I/II trial evaluating 
the maximal tolerated dose and primary tumor control rate for 
patients with central tumors using various five-fraction SBRT 
regimens, our data indicates that 50 Gy in four or five frac-
tions for central tumors is safe and effective without appearing 
to compromise OS or LC.
TABLE 3.  Univariable and Multivariable Overall Survival, Local Control, and Toxicity for Patients Treated for Central versus 
Peripheral Tumors (n = 251)
Univariable Multivariable (Central vs. Peripheral)
Outcome Central Peripheral p Value HR/OR 95% CI p Value
Overall survival (2 year) 71.6% 71.0% 0.30 HR 0.83 0.54–1.28 0.39
Local control (2 year) 87.1% 88.6% 1.00 HR 1.05 0.42–2.58 0.92
Acute grade ≥2 toxicity 26.1% 32.1% 0.33 OR 0.75 0.43–1.31 0.31
Acute grade ≥3 toxicity 4.5% 12.9% 0.03 OR 0.32 0.12–0.91 0.03
Late grade ≥2 toxicity 18.9% 28.1% 0.10 OR 0.61 0.33–1.11 0.10
Late grade ≥3 toxicity 8.1% 9.3% 0.82 OR 0.84 0.34–2.11 0.71
HR, hazard ratio; OR, odds ratio.
FIGURE 1.  Overall survival by tumor location. Solid line 
Peripheral tumors. Dotted line Central tumors.
FIGURE 2.  Local control by tumor location. Solid line 
Peripheral tumors. Dotted line Central tumors.
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